ClinicalTrials.gg
Status unknownNCT03415074K-DDDUpdated Feb 24, 2020

Could Ketoanalogue-supplemented Low Protein Diet Defer Dialysis in Advanced Diabetic Kidney Disease? (K-DDD)

An interventional study of Protein restriction in CKD Stage 4, sponsored by Anemia Working Group Romania. Status unknown at 1 site in Romania. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-02-24.

Sponsored by Anemia Working Group Romania · Not applicable, Interventional, and Prevention

How we know

The sponsor has not verified this record recently (last verified Feb 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

This is a prospective single center open label randomized controlled trial aiming to assess the effectiveness and safety of a low protein diet (0.6 g/kg-day, mainly vegetarian) supplemented with ketoanalogues of essential amino-acids (sLPD) as compared to a mild protein restriction (0.8 g/kg-day, MPD) in reducing Chronic Kidney Disease (CKD) progression, with a planned total duration is of 18 months.

Adult diabetic patients with CKD stage 4+ [estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease 4-variable (MDRD4) formula \<30 mL/min per year], with stable renal function (historical reduction of eGFR of \< 10 ml/min-year) , proteinuria > 3g/g creatininuria and good nutritional status (SGA A) will be enrolled.

Read the detailed description

Adult diabetic patients with Chronic Kidney Disease (CKD) stage 4+ (estimated GFR using the Modification of Diet in Renal Disease 4-variable, MDRD4, formula \<30 mL/min per year), with stable renal function (historical reduction of eGFR of \< 10 ml/min-year), proteinuria > 3g/g creatininuria and good nutritional status (SGA A) will be enrolled. Patients with evidence of active kidney disease (except proteinuria), with indication of etiological or pathogenic treatment, those with poor control of diabetes (HbA1c >8%), those with uncontrolled high blood pressure (≥155/85 mmHg), those with significant co-morbidities (heart failure, active liver disease, malabsorption, active infections, inflammatory diseases requiring corticosteroids), those with uremic symptoms (pericarditis, digestive disorders ) or malnutrition (SGA B or C, serum albumin \< 3.5 g/dl) will be excluded.

Eligible patients will enter a run-in phase (3 mo), when mild protein restriction (0.8g/kg dry ideal bw) will be initiated and compliance will be evaluated twice monthly.

Those who will prove compliant during the run-in phase and still fulfill the selection criteria will be randomized 1:1 (computer-generated numbers) to receive the low protein diet (0.6 g/kg-day, mainly vegetarian) supplemented with ketoanalogues of essential amino-acids (Ketosteril 1 tb/10 kg dry bw) or to continue the mild protein restriction (0.8 g/kg-day).

The total recommended energy intake is of 30 kcal/kg of ideal dry body weight per day in all patients.

The primary composite endpoint is the need for RRT initiation or a more than 50% reduction in the initial eGFR any time during the assessment phase. The decision to initiate RRT will be made by the Ethical Committee of the Hospital, based on the clinical and laboratory data.

The need for RRT initiation, the quality of life [assessed by the Short Form-36 (SF-36) Questionnaire], the decline in GFR and the correction of metabolic complications of CKD [serum levels of urea, calcium, phosphates, serum parathyroid hormone levels, bicarbonate, potassium] will be secondary efficacy parameters.

Parameters of nutritional status (SGA, anthropometric and biochemical parameters), compliance to the diet, occurrence of any adverse event and the number of withdrawals will be safety variables.

All the parameters will be assessed at baseline, throughout the intervention phase and at end of the study.

02

Conditions studied

  • CKD Stage 4

Keywords

  • low protein diet
  • Diabetic Kidney Disease
03

In context

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

This study's planned enrollment of 120 is above the median of 78 across 389 interventional studies indexed under Diabetic Nephropathies.

Browse Diabetic Nephropathies studies →

Lead sponsor

Anemia Working Group Romania is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diabetic patients
  • CKD stage 4+ (estimated using the Modification of Diet in Renal Disease 4-variable, MDRD4, formula \<30 mL/min per year)
  • stable renal function (historical reduction of eGFR of \< 10 ml/min-year)
  • proteinuria > 3g/g creatininuria
  • good nutritional status (SGA A)

Exclusion criteria

Exclusion Criteria:

  • evidence of active kidney disease (except proteinuria)
  • indication for etiological or pathogenic treatment
  • poor control of diabetes ( >8%)
  • uncontrolled high blood pressure (≥155/85 mmHg)
  • significant co-morbidities (heart failure, active liver disease, malabsorption, active infections, inflammatory diseases requiring )
  • uremic symptoms (pericarditis, digestive disorders
  • or malnutrition (SGA B or C, serum albumin \< 3.5 g/dl)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Supplemented low protein diet (sLPD)

    Protein restriction to a low level (0.6 g/kg-day, mainly vegetarian) + ketoanalogues of essential amino-acids supplementation (Ketosteril 1 tb/10 kg dry bw)

    Behavioral: Protein restriction

  • Active comparator
    Mild protein restriction diet (MPD)

    Mild restriction in dietary protein intake (0.8 g/kg-day)

    Behavioral: Protein restriction

Interventions

  • BehavioralProtein restriction

    In both arms the dietary protein intake will be reduced. In the sLPD arm, the protein restriction is more severe and ketoanalogues of the essential aminoacids are offered.

06

What researchers measure

Primary outcomes

  1. CKD progression

    Percentage of patients requiring RRT initiation or a more than 50% reduction in the initial eGFR at anytime during the study

    Time frame: 15 months

Secondary outcomes

  1. Need for renal replacement therapy (RRT)

    Percentage of patients requiring RRT during the study

    Time frame: 15 months

  2. Patients' Quality of life

    Patients' Quality of life, assessed by the SF-36 Questionnaire

    Time frame: at baseline and than every 3 months up to 15 months

  3. Decline in eGFR

    Difference between eGFR at any timepoint and the initial eGFR

    Time frame: monthly up to 15 months

  4. Correction of nitrogen balance

    Serum urea

    Time frame: monthly up to 15 months

  5. Correction of metabolic acidosis

    Serum bicarbonate

    Time frame: monthly up to 15 months

  6. Correction of calcium metabolism abnormalities

    Serum calcium

    Time frame: monthly up to 15 months

  7. Correction of mineral metabolism abnormalities

    Serum phosphates

    Time frame: monthly up to 15 months

  8. Serum level of intact Parathyroid Hormone (iPTH)

    iPTH

    Time frame: monthly up to 15 months

  9. Nutritional status - Subjective Global Assessment (SGA)

    SGA

    Time frame: monthly up to 15 months

  10. Body Mass Index (BMI)

    BMI

    Time frame: monthly up to 15 months

  11. Tricipital Skin Fold (TSF)

    TSF

    Time frame: monthly up to 15 months

  12. Middle arm muscular circumference (MAMC)

    MAMC

    Time frame: monthly up to 15 months

  13. Serum albumin

    Serum albumin

    Time frame: monthly up to 15 months

  14. Serum cholesterol

    Serum cholesterol

    Time frame: monthly up to 15 months

  15. Inflammatory status

    Serum C-Reactive Protein (CRP)

    Time frame: monthly up to 15 months

  16. Compliance to the protein intake

    Achieved protein intake (urinary urea excretion, Mitch-Maroni's formula)

    Time frame: twice-a-month during the run-in phase, weekly for the first month after randomization, every 4 weeks during the next 6 months, and then every 3 months up to 15 months

  17. Compliance to the energy intake

    Achieved energy intake (3-days food dairy)

    Time frame: twice-a-month during the run-in phase, weekly for the first month after randomization, every 4 weeks during the next 6 months, and then every 3 months up to 15 months

  18. Occurence of the adverse events

    Occurence of any adverse event

    Time frame: twice-a-month during the run-in phase, weekly for the first month after randomization, every 4 weeks during the next 6 months, and every 3 months up to 15 months

07

Study locations

1 of 1 sites recruiting
  • "Dr Carol Davila" Teaching Hospital of Nephrology
    Bucharest, 010731, Romania
    Recruiting
08

References and documents

Publications

  • Mihalache A, Garneata L, Mocanu CA, Simionescu TP, Mircescu G. Low-salt low-protein diet and blood pressure control in patients with advanced diabetic kidney disease and heavy proteinuria. Int Urol Nephrol. 2021 Jun;53(6):1197-1207. doi: 10.1007/s11255-020-02717-2. Epub 2021 Jan 2. PubMed 33389459 ↗

Individual participant data

Plan to share: Yes — Unique patient number in the study, biological data; no data to enable patient identification will be provided

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: March 2022

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2019 (actual). Primary completion is estimated for Sep 2022, 35 months after the start.

Of 50 non-industry interventional studies with no phase under Diabetic Nephropathies, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's planned 35 months is above that.

Counting every sponsor, half of 51 studies reached it within 23 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2017
First posted
Jan 30, 2018
StartActual
Oct 1, 2019
Primary completionEst.
Sep 30, 2022
CompletionEst.
Mar 31, 2023
Last update
Feb 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03415074
Lead sponsor
Anemia Working Group Romania
Responsible party
Sponsor
First posted
Jan 30, 2018
Start date
Oct 1, 2019
Primary completion
Sep 30, 2022 (estimated)
Completion
Mar 31, 2023 (estimated)
Last update
Feb 24, 2020

Study contacts

Liliana Garneata, Assoc Prof
Contact
lilianagarna@yahoo.com
+40722619358
Gabriel Stefan, MD
Contact
gabriel_stefan@rocketmail.com
+40724906188
Gabriel Mircescu, Prof
study chair · Carol Davila University of Medicine and Pharmacy

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion